Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

CD38-negative relapse in multiple myeloma after daratumumab-based chemotherapy

J. Minarik, M. Novak, P. Flodr, J. Balcarkova, M. Mlynarcikova, P. Krhovska, T. Pika, Z. Pikalova, J. Bacovsky, V. Scudla,

. 2017 ; 99 (2) : 186-189. [pub] 20170606

Language English Country Great Britain

Document type Case Reports

Persistent link   https://www.medvik.cz/link/bmc18010604

We present a case report of a patient relapsing after anti-CD38 treatment (daratumumab). The phenotype of the disease changed during this treatment, and the myeloma clone became CD38 negative and daratumumab refractory. We expected clonal shift, however, based on immunophenotyping, cytogenetics and arrayCGH; the clone was identical as before daratumumab-based treatment with the exception of CD38 negativity. We suggest that the downregulation or loss of CD38 might be an epigenetic "escape mechanism" of malignant plasma cells from antibody-based treatment. The aim of our study was to point out the pitfalls of immunophenotyping and cytogenetics in both assessing the minimal residual disease and clone detection after monoclonal antibody-based therapy.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18010604
003      
CZ-PrNML
005      
20180419102434.0
007      
ta
008      
180404s2017 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/ejh.12902 $2 doi
035    __
$a (PubMed)28470777
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Minarik, Jiri $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic.
245    10
$a CD38-negative relapse in multiple myeloma after daratumumab-based chemotherapy / $c J. Minarik, M. Novak, P. Flodr, J. Balcarkova, M. Mlynarcikova, P. Krhovska, T. Pika, Z. Pikalova, J. Bacovsky, V. Scudla,
520    9_
$a We present a case report of a patient relapsing after anti-CD38 treatment (daratumumab). The phenotype of the disease changed during this treatment, and the myeloma clone became CD38 negative and daratumumab refractory. We expected clonal shift, however, based on immunophenotyping, cytogenetics and arrayCGH; the clone was identical as before daratumumab-based treatment with the exception of CD38 negativity. We suggest that the downregulation or loss of CD38 might be an epigenetic "escape mechanism" of malignant plasma cells from antibody-based treatment. The aim of our study was to point out the pitfalls of immunophenotyping and cytogenetics in both assessing the minimal residual disease and clone detection after monoclonal antibody-based therapy.
650    _2
$a antigeny CD38 $x antagonisté a inhibitory $x metabolismus $7 D051997
650    _2
$a monoklonální protilátky $7 D000911
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a biologické markery $7 D015415
650    _2
$a srovnávací genomová hybridizace $7 D055028
650    _2
$a cytogenetické vyšetření $7 D020732
650    _2
$a lidé $7 D006801
650    _2
$a imunofenotypizace $7 D016130
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a cílená molekulární terapie $7 D058990
650    _2
$a mnohočetný myelom $x diagnóza $x farmakoterapie $x genetika $x metabolismus $7 D009101
650    _2
$a prognóza $7 D011379
650    _2
$a recidiva $7 D012008
655    _2
$a kazuistiky $7 D002363
700    1_
$a Novak, Martin $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic.
700    1_
$a Flodr, Patrik $u Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic.
700    1_
$a Balcarkova, Jana $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic.
700    1_
$a Mlynarcikova, Miroslava $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic.
700    1_
$a Krhovska, Petra $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic.
700    1_
$a Pika, Tomas $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic.
700    1_
$a Pikalova, Zuzana $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic.
700    1_
$a Bacovsky, Jaroslav $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic.
700    1_
$a Scudla, Vlastimil $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic.
773    0_
$w MED00001620 $t European journal of haematology $x 1600-0609 $g Roč. 99, č. 2 (2017), s. 186-189
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28470777 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20180419102535 $b ABA008
999    __
$a ok $b bmc $g 1288089 $s 1007416
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 99 $c 2 $d 186-189 $e 20170606 $i 1600-0609 $m European journal of haematology $n Eur J Haematol $x MED00001620
LZP    __
$a Pubmed-20180404

Find record

Citation metrics

Archiving options